June 9, 2010
Watch Dr. Daniel Silver from the Dana-Farber Cancer Institute in Boston, MA, brief the Congressional Biomedical Research Caucus on PARP Inhibitors: A Breakthrough in Cancer Therapy. Dr. Daniel Silver as he discusses the exciting potential of PARP inhibitors. Clinical trials have already shown remarkable cancer-fighting activity of PARP inhibitors alone and also in conjunction with conventional chemotherapy. The PARP inhibitors are relatively free of side effects compared with conventional chemotherapy, and many are orally administered drugs, making them attractive as cancer therapeutics.

свернуть